Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.

Trial Details

NCT ID
NCT06788912
Phase
PHASE2
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pembrolizumab (neoadjuvant)
  • Cisplatin
  • Gemcitabine
  • Pemetrexed
  • Sacituzumab tirumotecan
  • H1 receptor antagonist
Locations (sample)
  • Daphne, Alabama, United States|30.60353,-87.9036
  • Santa Barbara, California, United States|34.42083,-119.69819
  • Lone Tree, Colorado, United States|39.55171,-104.8863
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Eugene, Oregon, United States|44.05207,-123.08675

Key Eligibility Criteria

  • Inclusion Criteria:
  • Has previously untreated and pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC)
  • Able to undergo protocol therapy, including necessary surgery
  • Confirmation that epidermal growth factor receptor (EGFR) -directed therapy is not indicated as primary therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →